Information Provided By: 
Fly News Breaks for February 25, 2019
ZTS
Feb 25, 2019 | 08:53 EDT
BMO Capital analyst Alex Arfaei raised his price target on Zoetis to $101 after its Q4 earnings beat, saying the company continues to meet or exceed high expectations. The analyst expects Zoetis to produce 2019 revenue at the top of its guidance range with "several sources of potential upside" but also keeps his Market Perform rating because of the limited visibility on the long-term prospects of its two major franchises - dermatology and Simparico Trio - given the high Street expectations for both.
News For ZTS From the Last 2 Days
ZTS
Apr 23, 2024 | 05:05 EDT
Barclays lowered the firm's price target on Zoetis to $230 from $260 and keeps an Overweight rating on the shares ahead of the Q1 report. The analyst expects the Q1 reports to provide continuing evidence of improvement in generics and biosimilars for the specialty pharmaceuticals group.
